


FORM PTO-1390 (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <b>514413-3899</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known see 37 C.F.R. 1.5) <b>10/018331</b>		
INTERNATIONAL APPLICATION NO. <b>PCT/EP00/02809</b>	INTERNATIONAL FILING DATE <b>30 MARCH 2000</b>	PRIORITY DATE CLAIMED <b>30 APRIL 1999</b>		
TITLE OF INVENTION <b>PROCESS FOR THE PREPARATION OF L-PHOSPHINOTHRICIN BY ENZYMATIC TRANSAMINATION WITH ASPARTATE</b>				
APPLICANT(S) FOR DO/EO/US <b>Dr. Klaus BARTSCH</b>				
<p>Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ul> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>				
<p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information:  PCT/RO/101, PCT/IB/301, 306, PCT/ISA/210 1 page Abstract</li> </ol>				
<u><b>EXPRESS MAIL</b></u> Mailing Label Number: <b>EV001583824US</b> Date of Deposit: <b>October 26, 2001</b> <p>I hereby certify that this paper or fee is being deposited with the United States Postal Service</p> <p>"Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents and Trademarks, Box PCT Washington, DC 20231.</p> <p><i>Charles J. ...</i> (Typed or printed name of person mailing paper or fee)</p> <p><i>Charles J. ...</i> (Signature of person mailing paper or fee)</p>				

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50) <b>10/018331</b>		INTERNATIONAL APPLICATION NO PCT/EP00/02809	ATTORNEY'S DOCKET NO 514413-3899
21. <input checked="" type="checkbox"/> The following fees are submitted		<b>CALCULATIONS PTO USE ONLY</b>	
<b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO...  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$1040.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4). .... \$710.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .... \$100.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>\$ 890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	<u>13 - 20 =</u>	<u>0</u>	x \$18.00
Independent Claims	<u>5 - 3 =</u>	<u>2</u>	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$ 1,058.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 C.F.R. 1.27 The fees indicated above are reduced by ½.		+	\$
		<b>SUBTOTAL =</b>	<b>\$</b>
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
<b>TOTAL NATIONAL FEE =</b>		<b>\$ 1,058.00</b>	
Fee for recording the enclosed assignments (37 CFR 1.21(h)) The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property		+	\$ 0.00
<b>TOTAL FEES ENCLOSED =</b>		<b>\$ 1,058.00</b>	
		Amount to be refunded:	\$
		charged:	\$
a. <input checked="" type="checkbox"/> One check in the amount of <b>\$1,058.00</b> to cover the above fees is enclosed.  b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>50-0320</b> . A duplicate copy of this sheet is enclosed.  d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>			
SEND ALL CORRESPONDENCE TO:  <b>WILLIAM S. FROMMER, ESQ.</b> <b>FROMMER LAWRENCE &amp; HAUG LLP</b> <b>745 FIFTH AVENUE</b> <b>NEW YORK, NEW YORK 10151</b>			
<b>WILLIAM F. LAWRENCE</b> <hr/> <b>NAME</b> <hr/> 28,029 <hr/> <b>REGISTRATION NUMBER</b>			
Dated: October 26, 2001			

10/018331

JC13 Rec'd PCT/PTO 26 OCT 2001  
514413-3899

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Dr. Klaus BARTSCH

Filed.: Filed Concurrently Herewith

Title of Invention: PROCESS FOR THE PREPARATION OF L-  
PHOSPHINOTHRICIN BY ENZYMIC  
TRANSAMINATION WITH ASPARTATE

745 Fifth Avenue  
New York, NY 10151


**EXPRESS MAIL**

Mailing Label Number. Ev001583824US

Date of Deposit October 26, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Honorable Commissioner of Patents and Trademarks, Washington, DC 20231

  
(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231


Sir:

Before the issuance of the first Office Action, please amend the above-identified application as follows:


**IN THE CLAIMS:**

Please cancel claim 1-13 and add new claims 14-26 as follows:

14. A process for preparing L-2-mino-4-(hydroxymethylphosphinyl)butyric acid (L-phosphinothricin, L-PPT) of the formula (I), its derivatives which are selected from the group of carboxylic esters and carboxamides and phosphinic esters and/or its respective salts



from 4-(hydroxymethylphosphinyl)-2-oxobutyric acid (HMPB, PPO) of the formula (II)



its derivatives which are selected from the group of carboxylic esters and carboxamides and phosphinic esters and/or its respective salts as acceptor by enzymatic transamination in the presence of aspartate as donor, where the transamination takes place in the presence of one or more acceptor-specific aspartate transaminases (Asp-TA) to give oxaloacetate and the compound of the formula (I), its derivatives and/or salts.

15. The process as claimed in claim 14, wherein the reaction of aspartate as donor and a compound of the formula II, its derivatives which are selected from the group of carboxylic esters and carboxamides and phosphinic esters and/or its respective salts as acceptor takes place in the presence of one or more thermally stable acceptor-specific aspartate transaminases.

16. The process as claimed in one or more of claims 14 to 15, wherein the

acceptor-specific aspartate transaminases have a low substrate specificity for pyruvate so that the formation of the by-product alanine is avoided as far as possible.

17. The process as claimed in one or more of claims 14 to 16, wherein pyruvate which is present is removed from the reaction mixture by physical, chemical and/or enzymatic means.

18. The process as claimed in claim 17, wherein the conversion of the pyruvate takes place in the presence of one or more acetolactate synthases (ALS) to give acetolactate.

19. The process as claimed in claim 17, wherein the conversion of the pyruvate takes place in the presence of a pyruvate decarboxylase to give acetaldehyde.

20. The process as claimed in claim 17, wherein the conversion of the pyruvate takes place in the presence of a pyruvate oxidase to give acetyl phosphate.

21. The process as claimed in one or more of claims 18 to 20, wherein the conversion of pyruvate takes place in the presence of a thermally stable enzyme.

22. The process as claimed in one or more of claims 14 to 21, wherein one or more of the transaminases are in immobilized form.

23. A microorganism with the deposition number DSM 13353.

24. A microorganism with the deposition number DSM 13354.

25. A microorganism with the deposition number DSM 13355.

26. A microorganism with the deposition number DSM 13356.


Patent  
514413-3899

**REMARKS**

Claims 1-13 have been cancelled, and new claims 14-26 have been added. These amendments to the claims reflect the amendments to the International Application made during the International Preliminary Examination of the application. The filing fee has been calculated based upon these new claims.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicant

By:   
Reg No 37,514  
William F. Lawrence  
Reg. No. 28,029  
  
Tel. (212) 588-0800

WO 00/66760

PCT/EP00/02809

1

Description

Process for the preparation of L-phosphinothricin by enzymatic transamination with aspartate

5

The invention relates to the technical area of the synthesis of crop protection agents, in particular the synthesis of L-2-amino-4-(hydroxymethylphosphinyl)butyric acid (L-phosphinothricin, L-PPT) from 4-(hydroxymethylphosphinyl)-2-oxobutyric acid (HMPB, PPO) by enzymatic transamination in the presence of aspartate in the presence of a PPO-specific aspartate transaminase (Asp-TA). The compound L-PPT, its salts and some derivatives thereof are herbicidal reactive non-proteinogenic amino acids or salts and derivatives thereof (DE-A-2717440). The L form in each case is biologically active whereas the D form in each case is virtually inactive (DE-A-2856260).

20

It has previously been disclosed that transaminases are particularly suitable, because of their high stereoselectivity and their relatively broad substrate specificity, in particular for the chiral enzymatic synthesis of amino acids from their corresponding keto acid precursors. One disadvantage for the industrial use of transaminases is, however, their equilibrium constant of about 1, so that only a 50% yield of the required product can generally be obtained (US-A-4,826,766). EP-A-0344683 and US-A-5,221,737 describe the preparation of the herbicidal agent

25

L-phosphinothricin [(L-homoalanin-4-yl(methyl)phosphinic acid, L-2-amino-4-(hydroxymethylphosphinyl)butyric acid, L-PPT)], a non-proteinogenic amino acid, by transamination from the corresponding keto acid [(2-oxo-4-(hydroxy)(methyl)phosphinoyl)butyric acid, PPO)] with 4-amino-butyrate:2-ketoglutarate transaminase (GABA transaminase, EC 2.6.1.19) from *Escherichia coli*. Quantitative conversion requires a large molar excess of the amino donor glutamate, which makes purification of the reaction product difficult.

35

One solution of this problem is possible by use of aspartate as amino donor, because the corresponding keto acid oxaloacetate is unstable in aqueous medium and spontaneously decarboxylates to pyruvate. Removal of one reaction product from the equilibrium makes back-reaction impossible and quantitative conversion is possible even on equimolar use

of keto acid and donor amino acid. A process of this type is described, for example, in EP-A-0135846.

However, application of this principle to the enzymatic synthesis of

5 L-phosphinothricin has not to date been possible because the described GABA transaminase does not accept aspartate as amino donor, nor was any other transaminase with joint specificity for L-phosphinothricin and aspartate known.

10 As an alternative, a coupled 2-enzyme system consisting of PPT-specific transaminase and glutamate:oxaloacetate transaminase (GOT, EC 2.6.1.1) has been proposed (EP-A-0249188 and EP-A-0477902). In this reaction procedure, the glutamate used in the synthesis of L-PPT is regenerated from aspartate by means of GOT. The aspartate transaminase itself has no

15 specificity for L-PPT/PPO. The spontaneous conversion of oxaloacetate into pyruvate also leads to a shift in the equilibrium in the direction of L-PPT synthesis for the overall reaction. In this case, quantitative product yields are possible on equimolar use of PPO and aspartate with distinctly less than an equimolar quantity of glutamate.

20 This coupled enzyme process makes it possible to reduce distinctly the overdosage of the donor amino acids present in the substrate solution compared with the acceptor keto acid PPO, which simplifies work-up of the product solution. However, it is still necessary in the coupled reaction


25 procedure to use glutamate which - in equilibrium with ketoglutarate - remains in the reaction product or must be removed by elaborate purification processes from the structurally very similar amino acid L-PPT. In addition, optimization of the reaction procedure is more difficult with 2 enzymes than with one enzyme because of the different kinetic

30 parameters.


Although previously disclosed aspartate transaminases such as, for example, GOT show no conversion of PPO, aspartate transaminases from microorganisms which likewise accept L-PPT/PPO with high specificity as substrate have now surprisingly been found. These enzymes catalyze direct transfer of the alpha-amino group of aspartate to PPO.

The present invention therefore relates to a process for the preparation of L-2-amino-4-(hydroxymethylphosphinyl)butyric acid (L-phosphinothricin,

L-PPT) of the formula (I), its derivatives and/or salts,



5 from 4-(hydroxymethylphosphinyl)-2-oxobutyric acid (HMPB, PPO) of the formula (II)



10 its derivatives and/or salts as acceptor by enzymatic transamination in the presence of aspartate as donor, the transamination taking place in the presence of one or more acceptor-specific, preferably PPO-specific, aspartate transaminases (Asp-TA) to give oxaloacetate and the compound of the formula (I), its derivatives and/or salts, preferably in the presence of  
 15 one or more thermally stable and/or isolated aspartate transaminase and very particularly preferably in the presence of one or more aspartate transaminases with minimal substrate specificity for pyruvate, so that formation of the by-product alanine can be reduced or substantially avoided.

20

Salts of L-PPT are generally salts with inorganic and/or organic acids or mono- and disalts with inorganic and/or organic bases. Salts with acids (acid addition salts) are, for example, salts with mineral acids such as hydrochloric acid (hydrochloride) or sulfuric acid (sulfates), or with carbonic

25 acid (carbonates, hydrogen carbonates) or with organic acids such as acetic acid (acetates), formic acid (formates), propionic acid (propionates) or tartaric acid (tartrates). Salts with bases are, for example, alkali metal and alkaline earth metal salts, ammonium salts, salts with organic amines such as primary, secondary or tertiary amines, and quaternary ammonium salts.

30

Derivatives are, for example, esters of L-PPT which are esterified on the

phosphinic acid group, for example esterified with C<sub>1</sub>-C<sub>12</sub>-alkanols such as methanol, ethanol, n-propanol, i-propanol, n-, i- and sec- or tert-butanol and C<sub>3</sub>-C<sub>6</sub>-cycloalkanols such as cyclohexanol. Derivatives are also esters of L-PPT which are alternatively or additionally esterified on the carboxylic acid group, for example with the aforementioned alcohols. Derivatives are also the carboxamide of L-PPT and its derivatives, where appropriate N-alkyl or N,N-dialkylamides with, preferably, 1 to 4 C atoms in the alkyl moiety.

5      Derivatives of PPO are, for example, its salts with inorganic and/or organic bases, and bases suitable therefor have already been mentioned in connection with L-PPT. Derivatives are, for example, also esters of PPO which are esterified on the carboxylic acid group or the phosphinic acid group or both. Alcohols suitable for the ester groups are formally the alcohols suitable for esters of L-PPT, preferably the alkanols mentioned there. Derivatives are also the carboxamide of PPO and its derivatives which are esterified on the phosphinic acid group, and, where appropriate, corresponding N-alkyl or N,N-dialkylamides.

10     Aspartate preferably designates L-aspartic acid or its salts, preferably alkali metal salts. However, it is also possible to employ mixtures of L-aspartic acid with D-aspartic acid, for example racemic D,L-aspartic acid, as aspartate.

15     An alternative possibility in the process of the invention is to remove pyruvate which is present where appropriate in the reaction mixture by physical, chemical and/or enzymatic means, preferably by conversion by means of enzymatic catalysis, for example by acetolactate synthase (ALS), pyruvate decarboxylase, pyruvate oxidase, in particular acetolactate synthase; the conversion of pyruvate very particularly preferably takes place in the presence of a relatively thermally stable enzyme. The enzymes used thus can be in immobilized form where appropriate.

20     Both substrates (donor and acceptor) are employed for example in a molar ratio of 0.5-2:1 (based on L-aspartic acid:PPO), preferably 0.75-1.5:1, in particular approximately equimolar. On use of mixtures of L- and D-aspartic acids (salts), the molar quantity of L-aspartic acid (salt) is decisive. PPO derivatives must be employed in molar quantities equivalent to PPO. The presence of glutamate in the substrate solution is unnecessary. Some of

25

the enzymes found exhibit excellent thermal stability. The process can therefore be carried out in a wide temperature range, for example at temperatures from 10 to 95°C, preferably from 40 to 90°C, in particular from 60 to 85°C. The preferred temperature range for enzymes which 5 display no particular thermal stability is from 20 to 70°C, in particular from 30 to 40°C.

The relatively high temperatures allow the reaction rate to be considerably speeded up, which also makes it possible for more concentrated substrate 10 solutions (10% strength) to be converted with high space/time yields. The reaction preferably takes place at a pH in the range from 6.5-10, preferably from 7 to 9, in particular from 7.5 to 8.5 in an appropriately suitable buffer system with a pKa in the range from 7-9, *inter alia* phosphate or tris buffer. Surprisingly, the enzymes which have been biochemically characterized in 15 detail have no specificity for GABA and thus differ distinctly from previously disclosed L-PPT/PPO-specific transaminases.

Particularly high conversion rates can be achieved in the reaction if the formation of alanine during the transamination can be avoided or 20 minimized. It is possible to use for this purpose where appropriate optimized ASP-TA variants without substrate specificity for pyruvate. An alternative possibility is for pyruvate to be removed physically, for example by use of selectively permeable membranes and/or chemically or enzymatically, for example by conversion with pyruvate decarboxylase, 25 pyruvate oxidase or acetolactate synthase, from the reaction mixture (see, for example, Taylor et al., TIBTECH (1998), vol. 16, 412-418; Fotheringham et al., CHIMICA OGGI/chemistry today (1997), 9/10, 33-38; WO 98/53088).

30 Purification of the product, L-PPT, from the reaction solution can take place where appropriate by known and conventional processes, for example by extraction with methyl isobutyl ketone or by a cation exchange chromatography, for example with Amberlite® IR 120 (manufactured by Sigma).

35

The process of the invention is explained further in the following examples and the invention is defined in the patent claims. The following examples are not to be understood as limiting in this regard.

Examples:

1.) Isolation of soil microorganisms with L-PPT-specific aspartate transaminase activity:

5

1 g of each of various soil samples (humus, loam, sand/Schwanheimer Dünne, Frankfurt) were extracted with 10 ml of 10 mM Na phosphate buffer, pH = 7.0, at room temperature for 1 h. Enrichment cultures in the following medium were inoculated from the extracts:

- 10 5 mM glucose
- 5 mM succinate
- 10 mM glycerol
- 10 mM PPO
- 10 mM L-aspartic acid
- 15 50 ml/l solution A
- 25 ml/l solution B

Solution A: 50 g/l K<sub>2</sub>HPO<sub>4</sub>

Solution B: 2.5 g/l MgSO<sub>4</sub>

- 20 0.5 g/l NaCl
- 25 ml/l from a stock solution containing:

1 g/l FeSO<sub>4</sub> × 7 H<sub>2</sub>O  
 0.22 g/l MnSO<sub>4</sub> × H<sub>2</sub>O  
 0.1 g/l H<sub>3</sub>BO<sub>3</sub>  
 0.1 g/l Na<sub>2</sub> MoO<sub>4</sub> × 2 H<sub>2</sub>O  
 0.18 g/l ZnSO<sub>4</sub> × 7 H<sub>2</sub>O  
 0.16 g/l CuSO<sub>4</sub> × 5 H<sub>2</sub>O  
 0.1 g/l CoCl<sub>2</sub> × 6 H<sub>2</sub>O  
 1 ml/l 1 N HCl

30

The cultures were incubated at 28°C and 200 rpm on a shaker for 3-5 days. Enrichment of microorganisms able to grow with L-aspartic acid as sole N source was possible from one of the soil samples tested (humus). The culture was passaged further in the same medium several times and then plated out on agar medium of the same composition to isolate single clones. After incubation at 28°C for 3-5 days, a total of 100 single colonies was isolated and again inoculated in liquid medium (see above). The isolation on agar plates was repeated 2 × more in order to ensure that pure cultures were obtained.

After these selection cycles, 20 individual strains able to grow with L-aspartic acid as sole N source were available.

- 5 To test for PPO/Asp transaminase activity, 2 ml cultures of each of the strains were grown as above. Then 400 µl of each of the cultures were permeabilized with 0.5% toluene, 0.5% ethanol at 37°C for 30 min. The cell pellets were each resuspended in 50 µl of reaction mix consisting of 50 mM PPO, 50 mM L-aspartic acid, 50 mM Tris/HCl, pH = 8.0, 10 µM pyridoxal phosphate and incubated at 28°C overnight.
- 10

For qualitative determination of the PPT formed, the reaction supernatants were diluted 1:5 in water and 5 µl portions thereof were analyzed by thin-layer chromatography on cellulose HPTLC plates (Merck) with n-butanol:glacial acetic acid: water = 60:15:25 as mobile phase. The amino acids were visualized by ninhydrin staining. It was possible with 4 strains (DSM 13353, DSM 13354, DSM 13355, DSM 13356; all the strains have been deposited at the "Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH") to detect the formation of phosphinothricin. The enantiomeric purity of the reaction product was by chiral HPLC [investigated with the separation column Chirex® (D) with penicillamine as matrix (manufactured by Phenomenex)] (mobile phase: 2 mM CuSO<sub>4</sub>, 10% methanol, flow rate: 0.5 ml/min, UV detection: 254 nm, retention times: L-PPT: about 17 min, D-PPT: about 21 min). It was possible thereby to detect L-PPT and no D-PPT as reaction product in all the 4 test samples investigated.

For preparation of L-PPT by biotransformation and a quantitative analysis of the progress of the reaction, 1 l cultures of each of the soil bacterial strains DSM 13354, DSM 13355 and DSM 13356 were grown in the medium as described on page 6 at 28°C for 48 hours. The cells were harvested by centrifugation, washed 1 x in 10 mM NaCl, 10 mM Na phosphate, pH = 7.5, and then lyophilized overnight.

To carry out the biotransformation, 200 mg dry biomass of each of the soil bacterial strains identified above were resuspended in 10 ml of the following substrate solution:

- 100 mM PPO
- 200 mM L-aspartic acid
- 100 mM Tris/HCl, pH = 8.0

1 mM pyridoxal phosphate

The mixtures were incubated on an incubating shaker at 200 rpm and 37°C. 200 µl samples were taken after 1, 2, 4, 8, 24 and 30 h and analyzed in the HPLC as described on page 7. The measured results for L-PPT and

5 L-aspartic acid are summarized in table 1. The maximum conversion rate achieved [produced L-PPT/PPO in the substrate × 100] was about 59% (DSM 13355).

10

Table 1: Progress of the PPO/aspartate transamination reaction by biotransformation with soil isolates

Strain	Reaction time [h]	L-PPT [mM]	Aspartic acid [mM]
DSM 13354	1	3.9	174.0
	2	5.7	150.0
	4	10.3	100.0
	8	23.8	30.3
	24	38.3	0
	30	48.4	0
DSM 13355	1	4.5	143.1
	2	7.7	122.7
	4	11.1	98.8
	8	24.8	76.4
	24	44.9	17.2
	30	59.1	9.8
DSM 13356	1	5.7	138.1
	2	8.4	124.4
	4	12.5	95.9
	8	27.5	58.8
	24	51.3	14.3
	30	49.6	7.2

15 \*: Reaction temperature: 37°C

2.) Detection of direct PPO/aspartate transamination with transaminase enzyme preparations:

5 A total of 7 different commercially available transaminases was tested for PPO/aspartate transamination. From microorganisms deriving (thermally stable transaminases AMN-001-01, -001-02, -001-03, -001-04, -001-05, contained in the aminotransferase test kit from Diversa CAT# AMN-001 (1998); glutamate-oxalacetate transaminase (GOT), glutamate-pyruvate 10 transaminase (GPT), Sigma). The enzyme preparations were dissolved with a protein concentration of 5 mg/ml in 50 mM Tris/HCl buffer, pH = 8.0, and then dialyzed against the same buffer at 4°C overnight. This was intended to remove amino donors and acceptors which are possibly present in the enzyme preparations and which might act as intermediate 15 carriers in the transamination. The enzyme solutions were then adjusted to 1 mg/ml and incubated in 50 µl mixtures with reaction buffer consisting of 50 mM PPO, 50 mM L-aspartic acid, 50 mM Tris/HCl, pH = 8.0, 10 µM pyridoxal phosphate for 1 h at the temperature optimal for the particular enzyme.

20 The enzyme tests were analyzed by thin-layer chromatography and chiral HPLC as described in example 1. Enantioselective formation of L-PPT by transamination from L-aspartic acid was detectable with 2 of the thermally stable enzymes, AMN-001-03 and AMN-001-04 (reaction temperature: 25 80°C). None of the other enzymes tested showed any reactivity.

3.) Quantitative investigation of the PPO/aspartate transamination with the thermally stable transaminase AMN-001-03:

30 Because the specific activity was relatively high, the transaminase AMN-001-03 was selected for more accurate characterization of the L-PPT synthesis reaction. 1 ml of a substrate solution consisting of 40 mM PPO, 48 mM L-aspartic acid, 50 mM Tris/HCl, pH = 8.0, 0.1 mM pyridoxal phosphate were incubated with 1 mg of AMN-001-03 transaminase at 35 80°C. To analyze the progress of the reaction, 50 µl aliquots were taken over a period of 24 h and frozen at -20°C. PPT and aspartate were determined in an amino acid analyzer (Biotronic LC 5001). The results are shown in table 2. Under the chosen conditions, the L-PPT synthesis reaction reached equilibrium after 2-4 h. The amino donor employed,

L-aspartic acid, was completely consumed after 7 h. A conversion rate [produced L-PPT/PPO in the substrate  $\times 100$ ] of about 75% was achieved.

Table 2: Progress of the PPO/aspartate transamination reaction with  
5 transaminase AMN-001-03

Reaction time [h]	L-PPT [mM]	Aspartate [mM]
0	0	53.4
1	9.5	47.8
2	20.8	33.8
4	25.7	12.5
7	29.7	0
24	28.1	0.4

\* : Reaction temperature: 80°C

10 4.) Enzymatic chiral synthesis of L-PPT from PPO and aspartate with  
partially purified thermally stable transaminase AMN-001-03:

15 Partially purified transaminase AMN-001-03 with a specific activity of 107 nkat/mg of protein (1 nkat = 1 nmol of aspartate/sec.) was employed for the synthesis experiments. The reaction solution with a volume of 1 ml contained 552 mM PPO (10%), 700 mM L-aspartic acid, 0.1 mM pyridoxal phosphate, pH = 8.0, adjusted with KHCO<sub>3</sub>, and 11.5 mg of enzyme. The mixture was incubated at 80°C.

Sampling and analysis took place as described in example 3.

20 The results are compiled in table 3. In this experiment, the reaction equilibrium was reached after only 1 h. The amino donor L-aspartic acid was almost completely consumed after 4 h. The conversion rate was about 52% and the space/time yield was 4.5 of [g of L-PPT/g of biocatalyst/h]. In 25 a parallel experiment with the same substrate solution and enzyme concentration but a reaction temperature of 60°C, a similar conversion rate was achieved although the reaction rate was distinctly reduced. The space/time yield was only 0.95 [g of L-PPT/g of biocatalyst/h]. These results demonstrate the great importance of the high thermal stability of the 30 transaminase for the conversion rate and an efficient reaction procedure.

## 11

The only moderate conversion rate of 52% is mainly attributable to the formation of the by-product alanine by transamination of pyruvate. Considerably higher conversion rates can be achieved if the production of alanine during the reaction is avoided.

5

Table 3: Preparation of L-PPT by transamination with partially purified thermally stable transaminase AMN-001-03


Reaction time * [h]	L-PPT [mM]	Aspartate [mM]	Alanine [mM]
0	0	700.0	0
0.5	155.3	405.8	0
1	286.4	193.1	98.7
2	288.5	15.2	181.5
4	284.0	1.9	284.1
8	251.9	1.3	234.5

10

\*: Reaction temperature: 80°C


Patent claims:

1. A process for preparing L-2-amino-  
4-(hydroxymethylphosphinyl)butyric acid (L-phosphinothricin, L-PPT)  
5 of the formula (I), its derivatives and/or salts



from 4-(hydroxymethylphosphinyl)-2-oxobutyric acid (HMPB, PPO)  
of the formula (II)

10



15

its derivatives and/or salts as acceptor by enzymatic transamination  
in the presence of aspartate as donor, where the transamination  
takes place in the presence of one or more acceptor-specific  
aspartate transaminases (Asp-TA) to give oxaloacetate and the  
compound of the formula (I), its derivatives and/or salts.

20

2. The process as claimed in claim 1, wherein the reaction of aspartate  
as donor and a compound of the formula II, its derivatives and/or  
salts as acceptor takes place in the presence of one or more  
thermally stable acceptor-specific aspartate transaminases.

25

3. The process as claimed in one or more of claims 1 to 2, wherein the  
acceptor-specific aspartate transaminases have a low substrate  
specificity for pyruvate so that the formation of the by-product  
alanine is avoided as far as possible.

30

4. The process as claimed in one or more of claims 1 to 3, wherein  
pyruvate which is present is removed from the reaction mixture by

physical, chemical and/or enzymatic means.

5. The process as claimed in claim 4, wherein the conversion of the pyruvate takes place in the presence of one or more acetolactate synthases (ALS) to give acetolactate.
- 10 6. The process as claimed in claim 4, wherein the conversion of the pyruvate takes place in the presence of a pyruvate decarboxylase to give acetaldehyde.
- 15 7. The process as claimed in claim 4, wherein the conversion of the pyruvate takes place in the presence of a pyruvate oxidase to give acetyl phosphate.
- 20 8. The process as claimed in one or more of claims 5 to 7, wherein the conversion of pyruvate takes place in the presence of a thermally stable enzyme.
9. The process as claimed in one or more of claims 1 to 8, wherein one 20 or more of the transaminases are in immobilized form.
10. A microorganism with the deposition number DSM 13353.
11. A microorganism with the deposition number DSM 13354.
- 25 12. A microorganism with the deposition number DSM 13355.
13. A microorganism with the deposition number DSM 13356.

AGR 1999/M 210

### Abstract

Process for the preparation of L-phosphinothricin by enzymatic transamination with aspartate

The patent application describes a process for the enzymatic chiral synthesis of L-phosphinothricin by transamination from its corresponding keto acid PPO with aspartate as amino donor. It is possible by a suitable reaction procedure to achieve a quantitative conversion on use of approximately equimolar amounts of amino donor and acceptor with complete consumption of the donor amino acid aspartate. The use of thermally stable transaminases makes a higher reaction rate and correspondingly large space/time yields possible.





Appln. Ser. No. 10/018,331

Filed: October 26, 2001

10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600 610 620 630 640 650 660 670 680 690 700 710 720 730 740 750 760 770 780 790 800 810 820 830 840 850 860 870 880 890 900 910 920 930 940 950 960 970 980 990 1000

AGR 1999/M210 US PCT

## COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

### **Process for the preparation of L-phosphinothricin by enzymatic transamination with aspartate**

the specification of which

- is attached hereto
- was filed on as International Application

and including all the amendments through the date hereof.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

### **Prior Foreign Application(s) for which Priority is Claimed:**

Federal Republic of Germany, 19919848.9-42 of April 30, 1999

And I hereby appoint

William F. Lawrence, Registration No. 28,029, of the firm FROMMER LAWRENCE & HAUG, LLP whose post office address is 745 Fifth Avenue, New York, New York 10151, or their duly appointed associate, my attorneys, with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therewith, and specify that all communications about the application are to be directed to the following correspondence address:

William F. Lawrence, Esq.  
c/o FROMMER, LAWRENCE & HAUG LLP  
745 Fifth Avenue  
New York, New York 10151

Direct all telephone calls  
to: (212) 588-0800, to the  
attention of:  
William F. Lawrence

Filed: October 26, 2001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S) / Residence

1-00  
1) Dr. Klaus Bartsch , Im Kleinfeld 54, , 61462 Königstein, Germany

Signature:

Klaus Bartsch

Date: 72/77/2001

The inventor is citizen of **Germany**.

**DEK**

Post Office Address of all Inventors:

Aventis CropScience GmbH  
Patent- und Lizenzabteilung  
Industriepark Höchst  
Gebäude K 801  
D-65926 Frankfurt  
Germany